Phathom Pharmaceuticals (PHAT) Current Assets (2018 - 2026)
Phathom Pharmaceuticals (PHAT) posted quarterly Current Assets of $295.9 million for Q2 2026, up 35.2% year-over-year from $218.9 million in Q2 2025, and up 6.99% quarter-over-quarter from $276.6 million in Q1 2026.
Phathom Pharmaceuticals (PHAT) Current Assets (2018 - 2026) Analysis & Trends
Phathom Pharmaceuticals (PHAT) has reported Current Assets for 9 consecutive years, with $295.9 million the latest figure, recorded in Q2 2026.
- In Q2 2026, Current Assets rose 35.2% year-over-year to $295.9 million; the TTM figure through Jun 2026 stood at $295.9 million (up 35.2% YoY), while the FY2025 annual figure was $229.0 million, down 36.42% from the prior year.
- Current Assets rose to $295.9 million in Q2 2026 per PHAT's latest filing, from $276.6 million in the prior quarter.
- Across five years, Current Assets topped out at $397.4 million in Q4 2023 and bottomed at $139.8 million in Q1 2023.
- Historically, Current Assets has averaged $256.0 million across 5 years, with a median of $243.3 million in 2023.
- Annual changes were most pronounced in 2023 — Current Assets soared 147.6% — and 2025, when it slumped 44.42%.
- Phathom Pharmaceuticals' Current Assets stood at $160.5 million in 2022, then surged by 147.6% to $397.4 million in 2023, then declined by 9.38% to $360.1 million in 2024, then plunged by 36.42% to $229.0 million in 2025, then rose by 29.24% to $295.9 million in 2026.
- Business Quant data shows PHAT's Current Assets at $295.9 million in Q2 2026, $276.6 million in Q1 2026, and $229.0 million in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 12.54 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 18.45 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 8.07 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 4.03 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 7.22 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 11.83 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 1.76 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 4.62 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 1.63 Bn |
| 10 | Phathom Pharmaceuticals | 767.07 Mn | 581.73 Mn | 59.18 Mn | 295.92 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 295.92 Mn |
| Mar 31, 2026 | 276.57 Mn |
| Dec 31, 2025 | 228.97 Mn |
| Sep 30, 2025 | 207.78 Mn |
| Jun 30, 2025 | 218.88 Mn |
| Mar 31, 2025 | 264.90 Mn |
| Dec 31, 2024 | 360.13 Mn |
| Sep 30, 2024 | 373.82 Mn |
| Jun 30, 2024 | 304.79 Mn |
| Mar 31, 2024 | 340.31 Mn |
| Dec 31, 2023 | 397.43 Mn |
| Sep 30, 2023 | 226.73 Mn |
| Jun 30, 2023 | 257.72 Mn |
| Mar 31, 2023 | 139.84 Mn |
| Dec 31, 2022 | 160.51 Mn |
| Sep 30, 2022 | 197.81 Mn |
| Jun 30, 2022 | 209.26 Mn |
| Mar 31, 2022 | 145.74 Mn |
| Dec 31, 2021 | 186.53 Mn |
| Sep 30, 2021 | 225.31 Mn |